Ayati Devices Raises INR 15 Crore from Inflexor Ventures to Scale AI-Driven Diabetic Foot Diagnostics Platform
Ayati Devices, a Bengaluru-based medical technology and device manufacturing company developing precision diagnostic solutions for diabetic foot complications and peripheral vascular disease, has raised INR 15 Crore in a Pre-Series A funding round led by Inflexor Ventures. This marks the company's first institutional investment and will accelerate the commercialisation of its next-generation diagnostic technologies, expand its domestic and international presence, strengthen manufacturing capabilities, and deepen investments in research, regulatory approvals, artificial intelligence, and global talent. Ayati Devices has been incubated at IITB-SINE as part of the institute’s translational research program.
India's medical devices sector is accelerating on innovation and government incentives, even as diabetes becomes one of the world's biggest health challenges. Over 90 million Indians live with diabetes. Many lose foot sensation silently until complications strike, and over 50,000 lower-limb amputations occur in India each year, most preventable through timely diagnosis.
Founded by Nishant Kathpal, Ayati Devices builds clinically accurate, portable, and affordable diagnostic technologies that bring preventive care beyond tertiary hospitals into primary care centres and diabetes clinics. Ayati's portfolio covers the full diabetic foot diagnostic pathway. Vibrasense delivers clinician-independent neuropathy screening in under five minutes; Vibrasense+T adds large- and small-fibre nerve assessment. Vasosense detects Peripheral Artery Disease in two minutes without a specialist, while Angiocam turns real-time tissue perfusion imaging, once prohibitively expensive, into an accessible, portable tool. Completing the suite, the PODIA Trolley offers a pay-per-test screening station with zero upfront capital investment.
Ayati's technologies already hold regulatory clearances across major global markets, including CDSCO (India), the U.S. FDA, CE Mark (Europe), and approvals in Sri Lanka, Malaysia, and the UAE. The company has deployed over 10,000 devices across 30+ countries, backed by a growing international distributor network and clinical deployments at leading institutions such as Medicover Hospital and Aster Hospital. ..
The addressable market spans $15 billion globally and $1.4 billion in India alone, across diabetic neuropathy, peripheral vascular disease, and tissue perfusion imaging. Ayati's technology also extends into plastic surgery, wound care, burn management, cardiovascular diagnostics, and reconstructive medicine, widening its long-term potential.
The capital will fund Angiocam's commercialisation, expand go-to-market operations at home and abroad, strengthen manufacturing and supply chain capacity, accelerate R&D in AI-enabled diagnostics, secure further regulatory approvals, grow the IP portfolio, and build out engineering, clinical, regulatory, and global business development teams.
Looking ahead, Ayati will deepen its presence across Europe, the U.S., the Middle East, Southeast Asia, Australia, and Latin America through its distribution network, while evaluating direct commercial operations in key markets as demand scales. It will also expand its pay-per-test screening model across hospitals, primary care clinics, and community programmes, making preventive diagnostics far more accessible.
Commenting on the funding, Nishant Kathpal, Founder & CEO, Ayati Devices, said, "Diabetic foot remains one of the most overlooked healthcare challenges, despite being largely preventable with timely screening. At Ayati, we have focused on building technologies that make advanced diagnostics objective, affordable, and accessible beyond tertiary hospitals - right from primary care clinics to community screening programs. This investment marks an important milestone in our journey. It will accelerate our product roadmap, strengthen our global presence, and help us reach millions of patients before complications become irreversible. We are grateful to all our investors for believing in our vision of transforming diabetic foot care worldwide."
Explaining the investment rationale, Pratip Mazumdar, Partner, Inflexor Ventures, said, "India's medical devices sector, driven by innovation and government incentives, is rapidly expanding along with a strong structural tail-wing targeted towards localized technology and manufacturing. Ayati is a platform play in the medical devices sector and exactly the kind of company Inflexor exists to back: a founder with deep technical conviction, a product built from genuine clinical insight, and a platform that is already demonstrating adoption across both domestic and international markets. The scale of the opportunity is as large as the unmet need. Ayati's multi-product platform, proprietary hardware-software integration, and growing IP portfolio give it the moat to become the global standard of care in non-invasive vascular and neurological diagnostics."
The funding represents a significant milestone for Ayati Devices as it transitions from technology validation to accelerated commercial scale. With regulatory-ready products, global market access, and clinical adoption across multiple geographies, the company is set to make advanced diagnostics more affordable and accessible worldwide. As diabetes rises globally, Ayati aims to shift care from reactive treatment to early intervention, preventing amputations and improving outcomes for millions worldwide.
Muskaan Kapoor
